ELDN

Eledon Pharmaceuticals, Inc.

1.85 USD
+0.02 (+1.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Eledon Pharmaceuticals, Inc. stock is down -0.54% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 February’s closed higher than January.

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS.